NCT02368210 is a Phase 3 clinical trial of 122-0551 Foam in Plaque Psoriasis, sponsored by Therapeutics, Inc..

Who is sponsoring NCT02368210?

NCT02368210 is sponsored by Therapeutics, Inc..

What drugs are being tested in NCT02368210?

Interventions in NCT02368210: 122-0551 Foam, Vehicle Foam.

What condition does NCT02368210 study?

NCT02368210 studies Plaque Psoriasis.

Is NCT02368210 still recruiting?

NCT02368210 is currently completed. Last updated 24 October 2018.

Are results published for NCT02368210?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-10-24 · How we verify

NCT02368210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Completed Phase 3 Results posted Last updated 24 October 2018

What this trial tests

Phase 3 trial testing 122-0551 Foam in Plaque Psoriasis in 151 participants. Completed in 1 February 2017.

Timeline

1 January 2015

Primary endpoint
1 June 2015

1 February 2017

Quick facts

Lead sponsor	Therapeutics, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	151
Start date	1 January 2015
Primary completion	1 June 2015
Estimated completion	1 February 2017
Sites	8 locations across United States

Drugs / interventions tested

122-0551 Foam — full drug profile →
Vehicle Foam — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA)
Time frame: Day 15
The IGA score is a static evaluation of the overall or "average" degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. "Treatment success" is defined as a score of 0 or 1 representing "cleared" or "almost cleared" at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (

Sponsor's own description

This Phase 3 study (Study 306) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis
Bhatia N, Stein Gold L, Kircik LH, Schreiber R. · · 2019 · cited 2× · PMID 31424709

Verify or expand the search:

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Therapeutics, Inc. trials

Trials by the same sponsor.

NCT05363449 — Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis · Phase 1 · completed
NCT04080206 — A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis · Phase 2 · completed
NCT04243486 — A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis · Phase 2 · completed
NCT03897257 — A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis · Phase 2 · completed
NCT03759197 — A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02368210 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Therapeutics, Inc.
Last refreshed: 24 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02368210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing